These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30259180)

  • 1. Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy.
    Schuh RS; Bidone J; Poletto E; Pinheiro CV; Pasqualim G; de Carvalho TG; Farinon M; da Silva Diel D; Xavier RM; Baldo G; Matte U; Teixeira HF
    Pharm Res; 2018 Sep; 35(11):221. PubMed ID: 30259180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model.
    Fraga M; Bruxel F; Diel D; de Carvalho TG; Perez CA; Magalhães-Paniago R; Malachias Â; Oliveira MC; Matte U; Teixeira HF
    J Control Release; 2015 Jul; 209():37-46. PubMed ID: 25886705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice.
    Bidone J; Schuh RS; Farinon M; Poletto É; Pasqualim G; de Oliveira PG; Fraga M; Xavier RM; Baldo G; Teixeira HF; Matte U
    Int J Pharm; 2018 Sep; 548(1):151-158. PubMed ID: 29940298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers.
    Schuh RS; de Carvalho TG; Giugliani R; Matte U; Baldo G; Teixeira HF
    Eur J Pharm Biopharm; 2018 Jan; 122():158-166. PubMed ID: 29122734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic Nanoemulsions as a Gene Delivery System: Proof of Concept in the Mucopolysaccharidosis I Murine Model.
    Fraga M; de Carvalho TG; Diel Dda S; Kretzmann Filho NA; Teixeira HF; Matte U
    J Nanosci Nanotechnol; 2015 Jan; 15(1):810-6. PubMed ID: 26328445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy of Mucopolysaccharidosis Type I Mice: Repeated Administrations and Safety Assessment of pIDUA/Nanoemulsion Complexes.
    Fraga M; Schuh RS; Poletto É; de Carvalho TG; França RT; Pinheiro CV; Baldo G; Giugliani R; Teixeira HF; Matte U
    Curr Gene Ther; 2021; 21(5):464-471. PubMed ID: 33573568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model.
    Fraga M; de Carvalho TG; Bidone J; Schuh RS; Matte U; Teixeira HF
    Int J Nanomedicine; 2017; 12():2061-2067. PubMed ID: 28352175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical properties of cationic nanoemulsions and liposomes obtained by microfluidization complexed with a single plasmid or along with an oligonucleotide: Implications for CRISPR/Cas technology.
    Schuh RS; Poletto É; Fachel FNS; Matte U; Baldo G; Teixeira HF
    J Colloid Interface Sci; 2018 Nov; 530():243-255. PubMed ID: 29982016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system.
    Vera LNP; Schuh RS; Fachel FNS; Poletto E; Piovesan E; Kubaski F; Couto E; Brum B; Rodrigues G; Souza H; Giugliani R; Matte U; Baldo G; Teixeira HF
    J Gene Med; 2022 Apr; 24(4):e3410. PubMed ID: 35032067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
    Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
    J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
    Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
    Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
    J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
    Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
    Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice.
    Watson G; Bastacky J; Belichenko P; Buddhikot M; Jungles S; Vellard M; Mobley WC; Kakkis E
    Gene Ther; 2006 Jun; 13(11):917-25. PubMed ID: 16482204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymatic correction and cross-correction of mucopolysaccharidosis type I fibroblasts by adeno-associated virus-mediated transduction of the alpha-L-iduronidase gene.
    Hartung SD; Reddy RG; Whitley CB; McIvor RS
    Hum Gene Ther; 1999 Sep; 10(13):2163-72. PubMed ID: 10498248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
    Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
    Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
    Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
    Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.